Monoclonal Gammopathy of Undetermined Significance (MGUS) Overview

Save information for later
Sign Up

Learn About Monoclonal Gammopathy of Undetermined Significance (MGUS)

What is the definition of Monoclonal Gammopathy of Undetermined Significance (MGUS)?
Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop.
What are the alternative names for Monoclonal Gammopathy of Undetermined Significance (MGUS)?
  • Monoclonal gammopathy of undetermined significance
  • MGUS
Who are the top Monoclonal Gammopathy of Undetermined Significance (MGUS) Local Doctors?
Dr. Anthony D. Sung
Hematology Oncology | Hematology | Oncology
Dr. Anthony D. Sung
Hematology Oncology | Hematology | Oncology

University Of Kansas Hospital Authority

2650 Shawnee Mission Pkwy, 
Westwood, KS 
 (3.0 mi)
913-588-7750
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Sung is a Hematologist Oncology specialist and a Hematologist in Westwood, Kansas. Dr. Sung and is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Transplant. Dr. Sung is currently accepting new patients.

Dr. Mohammad Mozayen
Hematology Oncology | Oncology | Hematology
Dr. Mohammad Mozayen
Hematology Oncology | Oncology | Hematology

Midwest Oncology Associates LLC

2316 E Meyer Blvd, Research Medical Center, 
Kansas City, MO 
 (4.2 mi)
816-276-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Mozayen is a Hematologist Oncology specialist and an Oncologist in Kansas City, Missouri. Dr. Mozayen and is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Neuroendocrine Tumor, Lung Cancer, Childhood Iron Deficiency Anemia, and Familial Colorectal Cancer. Dr. Mozayen is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Al-ola Abdallah
Hematology Oncology | Oncology | Hematology
Dr. Al-ola Abdallah
Hematology Oncology | Oncology | Hematology

University Of Kansas Hospital Authority

2650 Shawnee Mission Pkwy, 
Westwood, KS 
 (3.0 mi)
913-588-7750
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Al-ola Abdallah is a Hematologist Oncology specialist and an Oncologist in Westwood, Kansas. Dr. Abdallah and is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Plasmacytoma, Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

View All Doctors
What are the latest Monoclonal Gammopathy of Undetermined Significance (MGUS) Clinical Trials?
CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study
CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study
Enrollment Status: Recruiting
Publish Date: February 13, 2025
Intervention Type: Other

Summary: The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active Myeloma (TACTAM)
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active Myeloma (TACTAM)
Who is this study for: Patients with Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Biological
Study Drug: TAA-specific CTLs
Study Phase: Phase 1

Summary: This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center